Revisiting Retinal Degeneration Hallmarks: Insights from Molecular Markers and Therapy Perspectives.

age-related macular degeneration diabetic retinopathy eye health glaucoma retinitis pigmentosa therapeutic strategies visual impairment

Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
23 Aug 2023
Historique:
received: 06 07 2023
revised: 04 08 2023
accepted: 14 08 2023
medline: 11 9 2023
pubmed: 9 9 2023
entrez: 9 9 2023
Statut: epublish

Résumé

Visual impairment and blindness are a growing public health problem as they reduce the life quality of millions of people. The management and treatment of these diseases represent scientific and therapeutic challenges because different cellular and molecular actors involved in the pathophysiology are still being identified. Visual system components, particularly retinal cells, are extremely sensitive to genetic or metabolic alterations, and immune responses activated by local insults contribute to biological events, culminating in vision loss and irreversible blindness. Several ocular diseases are linked to retinal cell loss, and some of them, such as retinitis pigmentosa, age-related macular degeneration, glaucoma, and diabetic retinopathy, are characterized by pathophysiological hallmarks that represent possibilities to study and develop novel treatments for retinal cell degeneration. Here, we present a compilation of revisited information on retinal degeneration, including pathophysiological and molecular features and biochemical hallmarks, and possible research directions for novel treatments to assist as a guide for innovative research. The knowledge expansion upon the mechanistic bases of the pathobiology of eye diseases, including information on complex interactions of genetic predisposition, chronic inflammation, and environmental and aging-related factors, will prompt the identification of new therapeutic strategies.

Identifiants

pubmed: 37685886
pii: ijms241713079
doi: 10.3390/ijms241713079
pmc: PMC10488251
pii:
doi:

Substances chimiques

Biomarkers 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : São Paulo Research Foundation
ID : 2021/08891-8
Organisme : São Paulo Research Foundation
ID : 2013/07467-1

Références

J Zhejiang Univ Sci B. 2021 Sept 15;22(9):746-756
pubmed: 34514754
Antioxidants (Basel). 2022 Sep 10;11(9):
pubmed: 36139862
Front Endocrinol (Lausanne). 2022 Aug 09;13:935244
pubmed: 36017322
Nat Rev Dis Primers. 2021 May 6;7(1):31
pubmed: 33958600
Diagnostics (Basel). 2023 Jan 04;13(2):
pubmed: 36672984
Int J Mol Sci. 2020 Jun 11;21(11):
pubmed: 32545285
Int J Mol Sci. 2022 Apr 28;23(9):
pubmed: 35563274
Cell Death Dis. 2022 Apr 9;13(4):323
pubmed: 35396550
Invest Ophthalmol Vis Sci. 2000 Dec;41(13):4293-9
pubmed: 11095629
Eye (Lond). 2022 Jun;36(6):1154-1167
pubmed: 34974541
Br J Ophthalmol. 2020 Jan;104(1):81-86
pubmed: 31055450
Am J Ophthalmol. 2013 Jan;155(1):1-35.e13
pubmed: 23245386
Ophthalmology. 2013 Apr;120(4):844-51
pubmed: 23332590
Int J Mol Sci. 2016 Sep 07;17(9):
pubmed: 27618014
Curr Diabetes Rev. 2014 Mar;10(2):100-12
pubmed: 24852439
Prog Retin Eye Res. 2018 Jan;62:1-23
pubmed: 29042326
Mol Vis. 2011;17:2618-27
pubmed: 22025897
iScience. 2018 Jun 29;4:1-19
pubmed: 30240733
Br J Ophthalmol. 2023 Feb;107(2):227-233
pubmed: 34526297
Expert Opin Biol Ther. 2018 Dec;18(12):1257-1270
pubmed: 30408422
Diabetologia. 2015 Jun;58(6):1231-8
pubmed: 25819896
Ophthalmology. 2010 Jan;117(1):63-70
pubmed: 19880184
PLoS One. 2015 Dec 14;10(12):e0144557
pubmed: 26658948
Clin Exp Ophthalmol. 2022 Mar;50(2):198-212
pubmed: 35037367
Life Sci. 2016 Oct 1;162:54-9
pubmed: 27497914
Curr Gene Ther. 2022;22(2):104-131
pubmed: 33902406
Surv Ophthalmol. 2016 Mar-Apr;61(2):187-96
pubmed: 26074354
BMC Med Genomics. 2021 Jan 4;14(1):1
pubmed: 33397358
Proc Natl Acad Sci U S A. 2007 Mar 13;104(11):4413-8
pubmed: 17360538
Clin Interv Aging. 2021 Jul 15;16:1367-1378
pubmed: 34290499
Biochem Biophys Res Commun. 2020 Oct 20;531(3):383-389
pubmed: 32800547
Ophthalmology. 2001 Nov;108(11):1943-53
pubmed: 11713061
Biology (Basel). 2022 Sep 10;11(9):
pubmed: 36138817
Annu Rev Biochem. 2017 Jun 20;86:715-748
pubmed: 28441057
Free Radic Biol Med. 2004 Sep 15;37(6):803-12
pubmed: 15384194
Hum Mol Genet. 2011 Jun 15;20(12):2472-81
pubmed: 21441570
Ophthalmology. 2021 Apr;128(4):490-493
pubmed: 33218709
EPMA J. 2023 Feb 17;14(1):53-71
pubmed: 36866159
Antioxid Redox Signal. 2010 Sep 15;13(6):797-805
pubmed: 20088705
Gene Ther. 2009 Jan;16(1):17-25
pubmed: 18701913
Hum Mol Genet. 2008 Aug 15;17(16):2474-85
pubmed: 18469340
Biomaterials. 2021 Oct;277:121074
pubmed: 34482086
J Ophthalmol. 2018 Feb 25;2018:3249064
pubmed: 29682340
Asia Pac J Ophthalmol (Phila). 2022 Jul-Aug 01;11(4):369-379
pubmed: 36041150
Pharmaceutics. 2023 Mar 06;15(3):
pubmed: 36986717
Biomed Pharmacother. 2023 Mar;159:114259
pubmed: 36652737
Mol Vis. 2021 Aug 20;27:480-493
pubmed: 34497454
Am J Ophthalmol. 2001 Nov;132(5):668-81
pubmed: 11704028
Mol Med Rep. 2016 Sep;14(3):2439-48
pubmed: 27485216
Int J Mol Sci. 2018 Jun 20;19(6):
pubmed: 29925789
Biomolecules. 2022 Nov 03;12(11):
pubmed: 36358978
J Ophthalmol. 2010;2010:
pubmed: 20871662
Dis Markers. 2019 May 06;2019:5820537
pubmed: 31198474
Cell Metab. 2021 Apr 6;33(4):818-832.e7
pubmed: 33548171
Invest Ophthalmol Vis Sci. 2003 Sep;44(9):3880-4
pubmed: 12939304
Gene Ther. 2022 Feb;29(1-2):81-93
pubmed: 34257417
Diabetes. 2000 Jun;49(6):1016-21
pubmed: 10866055
Ophthalmology. 2020 May;127(5):616-636
pubmed: 31864668
Vis Neurosci. 2013 Mar;30(1-2):5-20
pubmed: 23578808
Invest Ophthalmol Vis Sci. 2013 Dec 13;54(14):ORSF81-7
pubmed: 24335073
PLoS One. 2016 Mar 01;11(3):e0149663
pubmed: 26930483
Nat Commun. 2021 Oct 18;12(1):6072
pubmed: 34663817
Antioxid Redox Signal. 2021 Dec;35(16):1341-1357
pubmed: 33736457
Diabetes Care. 2003 Aug;26(8):2410-5
pubmed: 12882871
Diabetes Res Clin Pract. 2003 Aug;61(2):133-6
pubmed: 12951282
Int J Mol Sci. 2018 Apr 17;19(4):
pubmed: 29673160
Front Immunol. 2022 Oct 27;13:1059947
pubmed: 36389729
Diabetologia. 2011 Mar;54(3):690-8
pubmed: 21116609
Int J Mol Sci. 2023 Jan 30;24(3):
pubmed: 36768958
Exp Eye Res. 2019 Apr;181:356-366
pubmed: 30503749
Neuroscience. 2017 Feb 20;343:472-482
pubmed: 28017835
Eur J Ophthalmol. 2021 Mar;31(2):304-320
pubmed: 32962414
Mol Ther. 2020 Oct 7;28(10):2120-2138
pubmed: 32649860
Front Cell Dev Biol. 2023 Feb 08;11:1130058
pubmed: 36846582
Hum Genet. 2019 Sep;138(8-9):1043-1049
pubmed: 29556725
Diabetes Res Clin Pract. 2020 Sep;167:108361
pubmed: 32745697
J Diabetes Complications. 2002 Nov-Dec;16(6):391-4
pubmed: 12477623
Hum Mol Genet. 2010 Oct 1;19(19):3806-15
pubmed: 20631153
J Optom. 2017 Apr - Jun;10(2):71-78
pubmed: 27025415
Lancet. 2022 Feb 19;399(10326):729-740
pubmed: 35085502
Pharmaceutics. 2023 Feb 17;15(2):
pubmed: 36840007
Transl Vis Sci Technol. 2023 Feb 1;12(2):26
pubmed: 36795064
J Clin Endocrinol Metab. 2009 Feb;94(2):410-5
pubmed: 19066300
Prog Retin Eye Res. 2014 Nov;43:92-107
pubmed: 25128741
Invest Ophthalmol Vis Sci. 2007 Feb;48(2):705-14
pubmed: 17251469
Cell. 2021 Aug 5;184(16):4299-4314.e12
pubmed: 34297923
Surv Ophthalmol. 2023 May-Jun;68(3):332-346
pubmed: 36731638
Front Cell Dev Biol. 2018 Sep 19;6:110
pubmed: 30283779
Front Cell Dev Biol. 2022 May 09;10:900777
pubmed: 35615698
Hum Mol Genet. 2013 Aug 1;22(15):3165-73
pubmed: 23562823
Proc Natl Acad Sci U S A. 2021 May 25;118(21):
pubmed: 34006636
Arch Ophthalmol. 2009 Sep;127(9):1136-45
pubmed: 19752422
Sci Rep. 2021 Jan 21;11(1):2030
pubmed: 33479377
Diabetes Care. 2012 Mar;35(3):556-64
pubmed: 22301125
Med Sci (Paris). 2020 Jun-Jul;36(6-7):607-615
pubmed: 32614312
Diabetes. 1982 Jan;31(1):19-21
pubmed: 6759208
Lancet. 2006 Nov 18;368(9549):1795-809
pubmed: 17113430
J Ocul Pharmacol Ther. 2018 Dec;34(10):700-709
pubmed: 30412448
Ophthalmology. 2014 Nov;121(11):2081-90
pubmed: 24974815
Gene Ther. 2012 Feb;19(2):127-36
pubmed: 21975466
Redox Biol. 2020 Oct;37:101799
pubmed: 33248932
Am J Med Genet. 2002 May 15;109(4):278-83
pubmed: 11992481
Ophthalmol Sci. 2022 Oct 03;3(1):100229
pubmed: 36420180
Immunity. 2022 Sep 13;55(9):1627-1644.e7
pubmed: 35977543
Front Cell Neurosci. 2013 Jan 09;6:60
pubmed: 23316132
BMC Med Genet. 2017 Feb 1;18(1):10
pubmed: 28143435
Lancet Glob Health. 2014 Feb;2(2):e106-16
pubmed: 25104651
Nature. 1990 Jan 25;343(6256):364-6
pubmed: 2137202
BMC Med Genet. 2018 May 8;19(1):71
pubmed: 29739359
PLoS One. 2014 Nov 03;9(11):e111715
pubmed: 25364816
Pathophysiology. 2017 Dec;24(4):229-241
pubmed: 28732591
Biomed Res Int. 2014;2014:801269
pubmed: 25105142
Mol Vis. 2019 Feb 22;25:144-154
pubmed: 30820150
Cochrane Database Syst Rev. 2023 Jun 14;6:CD009300
pubmed: 37314061
Prog Retin Eye Res. 2008 Jul;27(4):391-419
pubmed: 18632300
Methods Cell Biol. 2023;175:97-128
pubmed: 36967148
Drug Discov Today. 2019 Aug;24(8):1614-1620
pubmed: 31173910
Am J Ophthalmol. 2013 Feb;155(2):342-353.e5
pubmed: 23111177
Exp Physiol. 2021 Jan;106(1):52-64
pubmed: 32386089
Diabetologia. 1997 Jul;40(7):764-9
pubmed: 9243096
Arch Ophthalmol. 2002 Jun;120(6):701-13; discussion 829-30
pubmed: 12049574
Diabetes. 2004 Mar;53(3):861-4
pubmed: 14988276
Invest Ophthalmol Vis Sci. 2011 Dec 02;52(13):9316-26
pubmed: 22110070
Front Cell Dev Biol. 2022 May 16;10:879957
pubmed: 35652098
Invest Ophthalmol Vis Sci. 1994 May;35(6):2887-94
pubmed: 8188484
Invest Ophthalmol Vis Sci. 2017 Dec 1;58(14):6513-6528
pubmed: 29288272
Jpn J Ophthalmol. 2020 May;64(3):243-249
pubmed: 32394134
Transl Vis Sci Technol. 2022 Jul 8;11(7):21
pubmed: 35877093
Invest Ophthalmol Vis Sci. 2020 Apr 9;61(4):31
pubmed: 32330228
Prog Retin Eye Res. 2021 May;82:100903
pubmed: 32950677
Cells. 2022 Feb 25;11(5):
pubmed: 35269429
Prog Retin Eye Res. 2015 Sep;48:40-61
pubmed: 25975734
N Engl J Med. 2004 Dec 30;351(27):2805-16
pubmed: 15625332
PLoS One. 2012;7(5):e36949
pubmed: 22615852
JCI Insight. 2023 Jun 22;8(12):
pubmed: 37345657
Pharmgenomics Pers Med. 2014 Dec 12;7:399-409
pubmed: 25548526
Ophthalmology. 2007 Feb;114(2):253-62
pubmed: 17270675
Nat Commun. 2021 Feb 24;12(1):1258
pubmed: 33627673
Invest Ophthalmol Vis Sci. 2022 Feb 1;63(2):1
pubmed: 35103752
J Clin Invest. 2022 Dec 1;132(23):
pubmed: 36453543
Retina. 2006 Oct;26(8):859-70
pubmed: 17031284
Trends Mol Med. 2002 Jul;8(7):319-23
pubmed: 12114110
Brain Res. 2010 Jan 13;1308:158-66
pubmed: 19853589
Mol Vis. 2006 Apr 11;12:336-41
pubmed: 16636650
Ophthalmology. 2018 Mar;125(3):369-390
pubmed: 29110945
Lancet. 2010 Jul 10;376(9735):124-36
pubmed: 20580421
Mol Vis. 2013 Nov 23;19:2360-72
pubmed: 24319330
Curr Diabetes Rev. 2020;16(3):242-247
pubmed: 30767747
Ophthalmology. 2011 Apr;118(4):642-8
pubmed: 21310492
Front Microbiol. 2022 Jul 18;13:934786
pubmed: 35923391
Nanotechnology. 2021 May 03;32(30):
pubmed: 33789258

Auteurs

João Gabriel Santos Rosa (JGS)

Immunoregulation Unit, Laboratory of Applied Toxinology (CeTICs/FAPESP), Butantan Institute, São Paulo 05503900, Brazil.

Geonildo Rodrigo Disner (GR)

Immunoregulation Unit, Laboratory of Applied Toxinology (CeTICs/FAPESP), Butantan Institute, São Paulo 05503900, Brazil.

Felipe Justiniano Pinto (FJ)

Immunoregulation Unit, Laboratory of Applied Toxinology (CeTICs/FAPESP), Butantan Institute, São Paulo 05503900, Brazil.

Carla Lima (C)

Immunoregulation Unit, Laboratory of Applied Toxinology (CeTICs/FAPESP), Butantan Institute, São Paulo 05503900, Brazil.

Monica Lopes-Ferreira (M)

Immunoregulation Unit, Laboratory of Applied Toxinology (CeTICs/FAPESP), Butantan Institute, São Paulo 05503900, Brazil.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH